




Committed to Safer Surfaces and Safer Lives

CSE: FNDX | OTCQB: FDXTF | FSE: E8D

SEPTEMBER 2025

FORWARD LOOKING STATEMENT: This presentation contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; expectations regarding industry trends, including with respect to the antimicrobial surface coating, and catheter markets, overall market growth rates and the Company's growth rates and growth strategies; that microbe repellent and kill technology is a promising, high-growth industry; the use of available funds; the performance of the Company's business and operations; the Company's expectations regarding revenues, expenses and anticipated cash needs; the intention to grow the Company's business, product pipeline and operations, including exploring and completing partnerships, acquisitions and licensing opportunities; the expected timing and completion of the Company's near-term objectives; the AI-diagnostic opportunity, benefits and development; laws and regulations and any amendments thereto applicable to the Company; the Company's competitive advantages and business and growth strategies; the expected development, timing and achievement of the Company's future product offerings, including catheters, spray, film products, AI-diagnostic and other applications; the intention to explore development opportunities using an AI diagnostic to detect microbial surface contamination; the Company's research and development initiatives and expected results thereof; the Company's growing patent portfolio; the Company entering into distribution, licensing, royalty, manufacturing and other business relationships, in Canada, the United States, and globally for its REPELWRAP™ film, spray, catheter coating or other products including the AI-diagnostic; the potential of the Company's technology to protect against the spread of pathogens on surfaces through repelling or killing bacteria and viruses that come in contact with its surface; that the Company's technology will bring significant value in controlling the spread of surface borne infectious diseases; trends regarding healthcare-acquired infections and antibiotic resistant pathogens; the Company's ability to access multi-million-dollar markets for any of its proposed products; proprietary REPELWRAP™ film and/or spray could be used on high-touch surfaces such as bed rails, doorknobs, and medical devices to help prevent pathogen transmission; the Company's nanotechnology has the potential to be applied to other types of surfaces and materials – such as catheters which could significantly help reduce infections caused by bacterial colony formation in long-use catheters, if the Company can successfully adapt their technology; the Company's intention to initially target REPELWRAP™ film towards healthcare settings and high traffic public touchpoints; that as the Company continues its product development, we may see it used to protect surfaces in other high traffic places like the transportation, education, sports and entertainment sectors; the growing global commitment to reduce the spread of pathogens; the timing and development of the Company's spray nanotechnology, including plans to enter into pilot scale-up upon completion of formulation, which could be easier to apply to many surfaces and expand potential market applications; the Company's organic growth strategy and expansion strategy; timing and development of a nano-coating for catheters; ability to develop an AI-diagnostic to detect surface contamination, and further development of core technology as well as into additional applications; expansion into vertical markets; access and receipt of non-dilutive funding; the achievement of revenues from any product through sales, licensing or distribution agreements; licensing or acquisition of additional complementary products that reduce pathogen spread; potential licensing, M&A and partnerships within the infectious disease space. Important factors that could cause future results to differ materially from those anticipated in these forward-looking statements include: product candidates only being in formulation/reformulation stages; limited operating history, no revenues and uncertainty around additional financing; negative cash flow history; no production history and lack of revenues from sales; no history of manufacturing or distribution; highly competitive industry; satisfying the terms of the License Agreement, Spray License Agreement and Collaborative Research Agreements between the Company and McMaster University and maintaining licenses in good standing; inability of McMaster University to satisfy the terms under the License Agreement, Spray License Agreement and Collaborative Research Agreements; ability to successfully complete scale-up and development of commercial film, spray, catheter and AI diagnostic or other products; ability to successfully complete real-world environmental testing of REPELWRAP™ film; research and development activities; reliance on grant funding; dependence on collaborative partners, licensors and others; no certainty entering into agreements to develop the AI-diagnostic including database development, machine learning, software development and other activities; no certainty of entering into formal distribution agreement with Sinelabs pursuant to LOI; changes and restrictions due to legal and regulatory requirements; dependence on each product's acceptance in the market; possibility of smaller market opportunities than anticipated; increasing regulatory and compliance costs for public companies; global economic instability; product liability claims and lawsuits; system failures; reliance on management and loss of key employees or inability to hire key personnel; limited experience of senior management in managing a public company; fraudulent or illegal activity by employees, contractors and consultants; inability to effect service of process on some of the Company's directors and officers; management's efforts and abilities; potential conflicts of interest; inability to protect intellectual property rights; inability to secure patents or grow its patent portfolio; infringement on proprietary rights of third parties; risks related to forward-looking information; volatility of the market price of the Company's common shares; potential dilution of the common shares; lack of an active, liquid and orderly trading market for the common shares; failure of securities or industry analysts to publish research or publish inaccurate or unfavorable research about the Company; inability or unwillingness to pay dividends; exchange rate fluctuations between the Canadian dollar and the U.S. dollar; effect of COVID-19 public health crisis or another global health pandemic; effect of general economic and political conditions; internal controls; and other risk factors set forth in the Company's public filings, publicly available through the Canadian Securities Administrators' SEDAR+ website at www.sedarplus.ca. The reader is urged to refer to the Company's other public filings, publicly available through SEDAR+ at www.sedarplus.ca for a more complete discussion of such risk factors and their potential effects. Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any Forward-looking statements contained in this presentation are expressly qualified in their entirety by this cautionary statement. While the information contained in this presentation is believed to be accurate, the Company expressly disclaims any and all liability for any losses, claims or damages of whatsoever kind based upon the information contained in, or omissions from, this presentation or any oral communication transmitted in connection therewith. In addition, none of the statements contained in this presentation are intended to be, nor shall be deemed to be, representations or warranties of the Company. Where the information is from third-party sources, the information is from sources believed to be reliable, but the Company has not independently verified any of such information contained herein. This presentation is not, and under no circumstances is to be construed as, a prospectus, an offering memorandum, an advertisement or a public offering of securities. Under no circumstances should the information contained herein be considered an offer to sell or a solicitation of an offer to buy any securities.

Developing Advanced Technologies for Surface Hygiene



Nano-coatings to protect high-touch surfaces, catheters and potentially other medical devices

Applying AI to mobile device images to detect surface contamination in real-time

Addressing the Challenge of Surface Contamination

The Problem

- Rise in antibiotic resistance (AMR) pathogens a global issue¹
- AMR could surpass cancer as leading cause of death by 2050²
- ~1.3 M deaths directly attributed to AMR globally in 2019³
- Trillion-dollar economic damages from infectious diseases globally by 2030³

Sources:

1. <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>
2. https://www.medscape.com/viewarticle/amr-could-surpass-cancer-leading-cause-death-2050-2024a1000lvr?_gl=1*1vitkn4*_gcl_au*MTQyNTg0NTc4OC4xNm3MTQ0MTQw&form=fpf
3. [Antimicrobial resistance](#)

The Solution


- FendX is focused on innovating solutions to support healthcare and public spaces through targeted surface protection technologies:
 - **AI diagnostic:** early detection of surface contamination early to help prevent the spread of potential pathogens
 - **Nano-coatings:** engineered to reduce surface contamination and limit spread

AI-Powered Microbial Surface Contamination Detection

Snap a Photo – Know Its Clean



AI Platform to Detect Microbial Contamination On Surfaces by Analyzing Mobile Device Images on Demand



Developing Software Using Microbial Imaging to Assess Surface Contamination via a Mobile Device



Capture Image



AI Analysis



**Verify
Microbial
Contamination**




**Clean
Contaminated
Surface**

- AI-powered software analyzes images to determine presence of microbial contamination
- Beta-testing to validate app's accuracy and readiness for market introduction

Advanced Nano-Coatings

PROTECTING SURFACES FROM
MICROBIAL THREATS



Antimicrobial & Antiviral Surface Nano-Coating: A Significant Opportunity

Estimated global market
revenue in 2031 (USD) ¹

~\$1.85 Bn

~ 8% CAGR (2024-2031)

Sources: 1. <https://www.futuremarketsinc.com/the-global-market-for-antimicrobial-antiviral-and-antifungal-nanocoatings-2021>



FendX has signed LOI with
Sinelabs to distribute future
nano-coated products

Nanoparticle-Infused Liquid Coating For Lasting Surface Protection

- **99%** reduction in MRSA and Pseudomonas aeruginosa ¹
- Easy application with brush, roller or sprayer to apply on high-touch surfaces
- Durable protection for long-lasting pathogen control
- Currently finalizing formulation and preparing for scale-up to larger batch sizes



1. Data on file

REPELWRAP™ Film

Nano-Coated Film to Protect Flat Surfaces

- >98% reduction in adhesion of a Covid-19 like virus, E. coli, B. subtilis and MRSA^{1,2}
- Intermediate scale-up manufacturing confirmed with Dunmore*
- Currently in beta-testing; results to date confirm film maintains its performance


Sources:

1. <https://pubs.acs.org/doi/10.1021/acsami.1c21476?ref=pdf>
2. <https://pubs.acs.org/doi/10.1021/acsami.3c11074>



* Dunmore International Corp. ("Dunmore"), a Steel Partners Holdings L.P. (NYSE:SPLP) operating company is a globally recognized film manufacturer.


Adhesive backing for application on high touch surfaces



Schematic illustration demonstrating how REPELWRAP™ film is applied.

Foley Catheter Lubricant-Coating For Infection Prevention

Reducing CAUTIs* Through Advanced Surface Coating Technology



- ~560,000 CAUTIs occur annually in the U.S., costing ~\$340 M in healthcare cost^{1,2}
- 95% reduction in biofilm formation³
- Currently in prototype development; next step is a proof-of-concept study

*Catheter Associated Urinary Tract Infections

Estimated global market revenue in 2033 (USD)⁴

~\$2.6 Bn

~ 5.4% CAGR (2023-2033)

Sources:

1. <https://www.nursingworld.org/practice-policy/work-environment/health-safety/infection-prevention/ana-cauti-prevention-tool/#:~:text=Click%20here%20for%20the%20companion,tool%20developed%20by%20leading%20experts.>
2. <https://www.hospitalsafetygrade.org/media/file/CAUTI.pdf>
3. [Data on File](#)
4. [Foley Catheter Market Size, Outlook & Growth Report 2023](#)

Building A Robust Patent Portfolio

AI Adaptive App (Triple A) Pathogen Detection Platform

- US Provisional Patent Application # 63/835,582

Lubricant Dilated Medical Catheters and Cannula and Uses Thereof

- US Provisional Patent Application # 63/832,648

Antimicrobial Coating for Long-Lasting Pathogen Control on High-Touch Surface

- US Provisional Patent Application filed

Open-Cell Foam Based Pathogen Remediation

- ***US Patent Application # 12,390,545 B2 - granted***

Open-Cell Foam Based Wound Treatment

- US Patent Application # 18/869,055
- Europe Patent Application # 23812600.7

Omniphobic Surfaces with Hierarchical Structures, and Methods of Making and Uses Thereof

- ***Chinese Patent Application # ZL 202080055337.6 - granted***
- ***US Patent Application # 17/616,374 - granted***
- ***Japan Patent Application # 2021-572059 - granted***
- ***Hong Kong Patent Application # 62022061224.1 - granted***
- ***Macao Patent Application # ZL 202080055337.6 - granted***
- Canada Patent Application # CA3142127
- Europe Patent Application # EP20819372.2

Methods of Making Omniphobic Materials with Hierarchical Structures and Uses Thereof

- US Patent Application # 18/683,578
- Canada Patent Application # CA3228893
- China Patent Application # CN202280056197.3
- Europe Patent Application # EP22857186.5
- Japan Patent Application pending

Fluorine-free Superhydrophobic Surfaces, Methods of Making and Uses Thereof

- US Patent Application # 18/683,559
- Canada Patent Application # CA3228891
- China Patent Application # CN202280056201.6
- Europe Patent Application # EP22857178.2
- Japan Patent Application pending

Proven Management Team

Dr. Carolyn Myers MBA, PhD

President, CEO & Director

- Accomplished senior pharma executive with extensive experience in creating, leading and growing health care businesses
- Principal of BioEnsemble LLC, advising start-ups and small pharma companies in developing their business strategy and planning
- Previously, Vice President International Business Development and Alliance Management at Allergan PLC (market cap \$83 Bn, 2017, now Abbvie); President of Dey Laboratories and President of Mylan Technologies Inc. (market cap \$9.2 Bn, 2011, now Viatris Inc.)

Rose Zanic CPA, CA

CFO & Corporate Secretary

- Over 25 years of capital markets and corporate finance expertise
- Significant experience advising Canadian public companies with financing, M&A transactions and providing public company administration.
- Previously Senior Vice-President, Corporate Finance at Wolverton Securities Ltd.
- Experience as a director and/or officer with several Canadian publicly listed companies
- Member of the TSX Venture Exchange BC Local Advisory Committee

Tash Yousuf BSc

Sr. Operations Manager

- Expertise in project and operations management
- Oversees business operations and product development, driving FendX's key projects forward
- Software Project Coordinator at Lenbrook International
- Operations Manager at Cineplex VIP Cinemas

Board of Directors & Advisors

Stephen Randall CPA, CGA
Independent Board Member
& Audit Committee Chair

- Senior financial manager and Director with over 40 years' experience.
- Served in senior financial roles with both private, publicly traded and start-up companies in the manufacturing, telecommunications, technology, and medical device sectors.
- Former Board Member, CFO and Corporate Secretary of Titan Medical Inc (TSX: TMD and NASDAQ: TMDI)

Pierre Soulard B.C.L., LLB, LLM
Independent Board Member

- Former Chief Legal Officer of CoinSmart (NEO: SMRT)
- Former partner, at Miller Thomson, a leading Canadian law firm.
- Focused on securities law, corporate finance, mergers and acquisitions and corporate governance for a wide range of national and international issuers and investors.

Dr. Carolyn Myers MBA, PhD
Board Member

- FendX President & CEO

Dr. Tohid Didar
Advisor

- Awarded the University Scholar title in 2024
- Canada Research Chair in NanoBiomaterials
- Associate Professor in the Department of Mechanical Engineering, School of Biomedical Engineering and a member of the Institute of Infectious Disease Research at McMaster University
- Co-inventor of REPELWRAP™ film
- Expert in biomedical devices, bio-sensing, microfluidics, bio-functional interfaces and bio-hybrid micro/nano robots
- Postdoctoral fellow at Wyss Institute at Harvard University

FendX Share Capital

Shares outstanding	9,001,969
Options	941,667
RSUs	28,750
Warrants	2,466,796
Fully diluted	12,439,182

September 10, 2025

A Leader in Surface Protection

- **Advanced Nano-Coating and AI Solutions:** developing advanced coatings and detection technologies to combat against microbial contamination
- **Robust IP Portfolio:** 6 granted patents with more in the pipeline; securing a strong competitive edge
- **High Growth Market Potential:** positioned to capture multi-billion-dollar opportunities across multiple industries
- **Strategic Partnerships:** driving speed to market and growth through collaborations in R&D, manufacturing and distribution
- **Experienced Leadership:** proven team track record of building and scaling successful businesses



Thank You!

investor@fendxtech.com / fendxtech.com

CSE: FNDX | OTCQB: FDXTF | FSE: E8D

SEPTEMBER 2025